Research ArticleOpen accessIn the author namesModeling Hepatocellular Toxicity of Enavatuzumab, a Humanized Anti-TweakR AntibodyDonghee Choi, Yanhong Zhu, Debra Tien Chao et al.In a Phase 1 clinical study, treatment with enavatuzumab, a humanized monoclonal antibody to TweakR, resulted in liver toxicity in a subset of patients. The objective of this current study was to evaluate the ability of preclinical studies to predict liver toxicity in humans. Enavatuzumab was evaluated in cynomolgus monkeys, where serum liver enzyme and cytokine levels were measured and … …American Journal of Pharmacology and Toxicology, Vol. 12, Issue 2 · 9 Nov 2017 · 7,719 accessesView PDFCite